文献速递免疫规划卫生政策与健康促进

扩大免疫规划50年对14种病原体的全球经济评估

Global, regional, and national impact of the Expanded Programme on Immunization against 14 pathogens from 1974 to 2024: an economic evaluation.
PubMed 文献 · Lancet Glob Health · 2026-06-04

该研究评估了WHO扩大免疫规划(EPI)1974至2024年间针对14种病原体的经济影响,覆盖194个成员国。

核心结论

  • EPI实施50年在全球、区域和国家层面均具高成本效益,尤其在高负担和低收入环境中回报显著。

研究设计与样本

  • 对194个WHO成员国1974年1月1日至2024年12月31日期间14种病原体的EPI进行经济评估,比较实际接种与无接种情景的成本和收益。

主要发现

  • 所有14种病原体疫苗的ICER均低于常规成本效果阈值。

临床怎么用

  • EPI应作为高成本效益的公共卫生投资持续维持和扩大,尤其在低收入和高疾病负担地区。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 2024 marked the 50th anniversary of the Expanded Programme on Immunization (EPI), launched by WHO. Despite its crucial role in preventing infectious diseases, EPI's 50-year economic impact has not been systematically evaluated. This study aims to estimate the benefit-cost ratios (BCRs) and incremental cost-effectiveness ratios (ICERs) of EPI at global, regional, and national levels. METHODS: We conducted an economic evaluation of EPI for 14 globally important pathogens with robust long-term data availability: Corynebacterium diphtheriae (diphtheria), Haemophilus influenzae type b, hepatitis B virus (hepatitis B), Japanese encephalitis virus (Japanese encephalitis), measles virus (measles), Neisseria meningitidis group A (meningitis A), Streptococcus pneumoniae, Bordetella pertussis (pertussis), poliovirus (polio), rotavirus, rubella virus (rubella), Clostridium tetani (tetanus), Mycobacterium tuberculosis (tuberculosis), and yellow fever virus (yellow fever) from Jan 1, 1974, to Dec 31, 2024, across 194 WHO member states. We compared costs (procurement, administration, and family additional costs from time spent synthesised from authoritative global databases and systematic literature reviews) and benefits (primarily averted mortality retrieved from published global burden estimates) between observed EPI implementation and a counterfactual scenario of no vaccination, from which BCRs and ICERs were derived. FINDINGS: From 1974 to 2024, the cost of EPI reached US$937 billion (95% CI 699-1187), offset by $15 050 billion (12 609-17 605) in averted productivity losses due to mortality (aggregate BCR 16·06 [95% CI 10·62-25·20]; ICER cost-saving). Immunisation against all 14 pathogens showed favourable economic outcomes. Measles vaccination produced the highest BCR (73·97 [45·78-124·06]), and the ICERs for all vaccines remained below conventional cost-effectiveness thresholds. EPI against 14 pathogens in aggregate achieved cost savings (BCR>1) in all 194 WHO member states. Economic returns varied across six WHO regions and four World Bank income groups, with the Eastern Mediterranean region (BCR 17·22 [11·22-28·67]) and low-income countries (BCR 23·63 [16·87-34·32]) showing the highest BCRs. INTERPRETATION: The 50-year EPI has proven highly cost-effective at global, regional, and national levels, and remains a worthwhile investment. The EPI delivered impactful life-saving benefits and favourable economic returns, especially in high-burden and low-income settings. FUNDING: The National Natural Science Foundation of China, the China Postdoctoral Science Foundation, the Vaccine Impact Modelling Consortium, and the Japan Agency for Medical Research and Development.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Lai X, Abbas K, Pouwels KB, et al. Global, regional, and national impact of the Expanded Programme on Immunization against 14 pathogens from 1974 to 2024: an economic evaluation. Lancet Glob Health. 2026. PMID: 42242275. doi:10.1016/j.langlo.2026.103965

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。